Line 33: |
Line 33: |
| |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |
| |- | | |- |
− | |Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| || | + | |Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| || |
− | |
| + | |Chronic Neutrophilic Leukemia (CNL) |
− | |
| + | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally |
| |- | | |- |
− | |Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| || | + | |Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| || |
− | | | + | |Chronic Eosinophilic Leukemia, Not Otherwise Specified |
− | | | + | |Chelsea D. Kramish; Daynna J.Wolff |
| |- | | |- |
− | |Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR|| || | + | |Polycythaemia vera||Disease|| || || || || ||FQR|| || |
− | | | + | |Polycythemia Vera (PV) |
− | | | + | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |
| |- | | |- |
| |Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| || | | |Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| || |
− | | | + | |Essential Thrombocythemia (ET) |
| | | | | |
| |- | | |- |